Sunesis Pharmaceuticals Rating Lowered to Neutral at Wedbush (SNSS)
Sunesis Pharmaceuticals (NASDAQ:SNSS) was downgraded by research analysts at Wedbush from an “outperform” rating to a “neutral” rating in a report released on Friday, TheFlyOnTheWall.com reports.
Shares of Sunesis Pharmaceuticals (NASDAQ:SNSS) opened at 7.78 on Friday. Sunesis Pharmaceuticals has a 52-week low of $3.84 and a 52-week high of $8.46. The stock’s 50-day moving average is $6.69 and its 200-day moving average is $6.05. The company’s market cap is $470.2 million.
Sunesis Pharmaceuticals (NASDAQ:SNSS) last issued its quarterly earnings data on Tuesday, August 5th. The company reported ($0.20) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.17) by $0.03. The company had revenue of $2.00 million for the quarter, compared to the consensus estimate of $1.32 million. During the same quarter in the prior year, the company posted $0.18 earnings per share. The company’s quarterly revenue was up .0% on a year-over-year basis. Analysts expect that Sunesis Pharmaceuticals will post $-0.74 EPS for the current fiscal year.
Sunesis Pharmaceuticals, Inc (NASDAQ:SNSS) is a biopharmaceutical company focused on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.